Alentis Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications. We are rapidly advancing our pipeline of antibodies and antibody-drug conjugates through clinical development.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2019
  • Number of employees in Switzerland
    20-49
Key business

You may also be interested in